Clinical Trial Update: Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) [Phase 2]

View source ↗

Summary

Phase II trial update on Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute GVHD after myeloablative allogeneic HSCT; trial completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation
• Leukemia

Drugs mentioned

• Efprezimod Alfa (CD24Fc, MK-7110) (CD24Fc)

Snippet

Sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2021-06-18